Physician profile
Tam Chieu
NPI 1730726084
$4,842.90
in general payments reported to CMS, 2019-2025
24 companies · $2,422 in 2025
The $2,422 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.53 · 2022: $449 · 2023: $1,529 · 2024: $431 · 2025: $2,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692 · Travel and Lodging: $1,625 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.03 |
| Travel and Lodging | $1,624.87 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,865.04 | 2023-2025 | Urolift, Barrigel, Deknatel |
| Axonics, INC. | $1,186.30 | 2022-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $344.95 | 2022-2024 | Myrbetriq, Xtandi |
| Boston Scientific Corporation | $228.27 | 2022-2025 | Axonics, Rezum Generator, Spaceoar Vue System - 10ml |
| C. R. Bard, INC. & Subsidiaries | $154.74 | 2023-2024 | Bard Urinary Drainage Bag |
| Pfizer INC. | $146.46 | 2025 | |
| Urogen Pharma, INC. | $134.81 | 2024-2025 | |
| Abbvie INC. | $125.72 | 2022-2025 | |
| Endo USA, INC. | $115.35 | 2024-2025 | Xiaflex |
| Sumitomo Pharma America, INC. | $76.86 | 2023-2025 | Orgovyx, Gemtesa |
| Urovant Sciences INC | $73.55 | 2022 | |
| Progenics Pharmaceuticals, INC. | $63.76 | 2022-2023 | Pylarify |
| Endo Pharmaceuticals INC. | $59.89 | 2023-2024 | Xiaflex |
| Becton, Dickinson and Company | $42.88 | 2023 | Bard Urinary Drainage Bag |
| Rochester Medical Corporation | $37.72 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $30.76 | 2023 | Provenge |
| Tolmar, INC. | $24.84 | 2023 | |
| Olympus America INC. | $23.50 | 2025 | Itind System |
| Procept Biorobotics Corporation | $23.06 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.87 | 2022 | |
| Aroa Biosurgery Incorporated | $19.67 | 2025 | |
| Kerecis Limited | $19.62 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Myriad Genetic Laboratories, INC. | $13.75 | 2024 | Prolaris |
| Tolmar Pharmaceuticals, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tam Chieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.